<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362314">
  <stage>Registered</stage>
  <submitdate>28/03/2012</submitdate>
  <approvaldate>3/04/2012</approvaldate>
  <actrnumber>ACTRN12612000381886</actrnumber>
  <trial_identification>
    <studytitle>High Concentration Oxygen in Fibrotic Lung Disease</studytitle>
    <scientifictitle>Response of Patients with Fibrotic Lung Disease to Hyperoxia and Normoxia, as Measured by Carbon Dioxide Levels</scientifictitle>
    <utrn>U1111-1129-5712</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fibrotic Lung Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>50% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive airway pressure. Followed by a 30 minute washout period.</interventions>
    <comparator>21% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive aiway pressure. Followed by a 30 minute washout period.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.</outcome>
      <timepoint>30 minutes.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.</outcome>
      <timepoint>10 and 20 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minute ventilation, adjusted for baseline, calculated using a flow sensor attached to the expiratory port of the participant's mask.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of dead space to tidal volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in transcutaneous carbon dioxide greater than or equal to 4mmHg, as measured by a TOSCA monitor.</outcome>
      <timepoint>30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in transcutaneous carbon dioxide greater than or equal to 10 mmHg, as measured by a TOSCA monitor.</outcome>
      <timepoint>30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tidal volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of dead space, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alveolar volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Alveolar minute ventilation, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oxygen saturations, adjusted for baseline, as recorded on the TOSCA via continuous electronic recording data download.</outcome>
      <timepoint>Continuously over the time course of the intervention and washout period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of baseline transcutaneous carbon dioxide, as recoded via the TOSCA, on outcome.</outcome>
      <timepoint>Value from baseline.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart rate, adjusted for baseline, as recorded on the TOSCA.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory rate, measured from capnography equipment.</outcome>
      <timepoint>10, 20 and 30 minutes.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Fibrotic lung disease by doctor's diagnosis and evidence of fibrosis on CT scanning</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Baseline transcutaneous carbon dioxide of greater than or equal to 60mmHg
Diagnosis of chronic obstructive pulmonary disease
FEV1:FVC less than or equal to 70%
Vital capacity greater than 80%
Over 20 pack year smoking history
Obesity (body mass index greater than or equal to 40)
Any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Following explaination of the trial and consent, participants will be assessed for eligibility. If eilgible, participants will be randomised to the order of interventions (21% oxygen and 50% oxygen). This order will be available to an investigator who is not administering treatment, assessing outcomes or analysing data. Their role is to make available the gas bottles and bags (containing either 21% or 50% oxygen) in the randomised order. The labels on the bottles will be covered to maintain blinding of other investigators and the participant.</concealment>
    <sequence>By computer</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>18/04/2012</anticipatedstartdate>
    <actualstartdate>24/07/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Janine Pilcher</primarysponsorname>
    <primarysponsoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>Level 3 - ProCARE Building, Grafton Mews, at 110 Stanley Street, Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Medical Research Institute of New Zealand</fundingname>
      <fundingaddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Richard Beasley</sponsorname>
      <sponsoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Kyle Perrin</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Pip Shirtcliffe</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mitesh Patel</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mathew Williams</othercollaboratorname>
      <othercollaboratoraddress>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Mark Weatherall</othercollaboratorname>
      <othercollaboratoraddress>Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Oxygen therapy has been shown to increase carbon dioxide in the blood of patients with certain repiratory conditions. This study aims to find out if oxygen therapy increases carbon dioxide levels in patients with fibrotic lung disease and, if so, how.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee: Central</ethicname>
      <ethicaddress>1 The Terrace, Wellington 6011</ethicaddress>
      <ethicapprovaldate>23/03/2012</ethicapprovaldate>
      <hrec>CEN/11/12/074</hrec>
      <ethicsubmitdate>21/12/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021</address>
      <phone>+64 4 8050241</phone>
      <fax>+64 4 3895707</fax>
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janine Pilcher</name>
      <address>MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021  </address>
      <phone>+6448050241</phone>
      <fax />
      <email>janine.pilcher@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>